drugset / Trial / NCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Phase 2
Recruiting
43 enrolled
H. Lee Moffitt Cancer Center and Research Institute
BeOne Medicines · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Timeline
- Start
- 2024-04-19
- Primary completion
- 2029-03
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 1400 mg | Intravenous |
| Subject | Zanubrutinib | Small molecule | 320 mg | Oral |